Gefitinib, which is selective for the epidermal growth factor receptor (EGFR), was developed as an oral cancer treatment directed against non-small cell lung cancer (NSCLC), and is effective in patients with specific mutations of EGFR [7,8,9]. This evidence concerns the gene EGFR and lip and oral cavity carcinoma.